Tissue
Plasminogen Activator Market, By Dosage (2mg, 50mg, and 100mg), By Route of
Administration (Intravenous and Regional Intra-Arterial), By Application (Blood
Clots, Pulmonary Embolism, Myocardial Infarction, and Stroke), and By Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -
Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Tissue plasminogen activator
(tPA) is an enzyme associated with the disintegration of blood clots. It is a
serine protease present in endothelial cells. With the help of serine protease,
the conversion of plasminogen to plasmin is catalyzed. Serine protease is a major enzyme for clot
disintegration.
tPA is also be produced by using
recombinant technology techniques known as recombinant tissue plasminogen
activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase.
These enzymes are used in clinical treatment of thrombotic stroke or embolic
stroke. tPA is a drug that dissolves blood clots. It is a thrombolytic agent
which can be administrated into the veins.
Global Tissue Plasminogen
Activator Market: Drivers
Tissue plasminogen activator is
the first and only drug approved by the FDA in 1996 for the treatment of acute
ischemic stroke. Increasing incidences of stroke has boosted the tissue
plasminogen activator market size. According to John Hopkins Medicines (JHM) in
the U.S., around 795,000 people in the U.S. suffer from stroke per year, as
reported in 2014. According to the World Health Organization (WHO), stroke is
the second leading cause of death and the third leading cause of disability,
worldwide, as reported in 2012. This is one of the major factors driving the
tissue plasminogen activator market growth.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2469
Increasing prevalence of stroke
incidences in growing geriatric population is another major factor driving the
market size. As per the Public Health England (PHE), around 38% of people
suffering from strokes were aged 40 to 69 in 2018. Moreover, tissue plasminogen
activator market revenue is witnessing further increase due to awareness about
stroke and its symptoms. In 2015, the Centers of Disease Control and Prevention
(CDC) stated that around 38% of people were able to recognize the major
symptoms of stroke and were treated at the right time.
Global Tissue Plasminogen
Activator Market: Restraints
The side effects such as nausea,
vomiting, dizziness, and fever, of the drug is one of the factors hindering
tissue plasminogen activator market growth. Major side effects include
hypertension, intracranial hemorrhage, systemic hemorrhage, angioedema, and
others. tPA also causes complications of left ventricle. In 2011, the National
Center for Biotechnology Information recorded around 2% to 5% of patients with
acute ischemic stroke receive rtPA in the U.S. In 2015, CDC reported around
140,000 deaths due to unavailability and adverse effects of tPA in the U.S.
Moreover, tissue plasminogen
activator market growth can also be hampered by substitute product approvals by
the Food and Drug Administration (FDA). For instance, after the approval of
stent retriever by FDA, in 2012, the global tissue plasminogen activator market
growth was affected, since tPA is not effective for major blood clots in
comparison to the stent retriever thrombectomy.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/tissue-plasminogen-activator-market-2469
Global Tissue Plasminogen Activator
Market: Regional Analysis
North America is the leader in
the global tissue plasminogen activator market, owing to rising awareness about
stroke and huge spending on treatment of stroke. For instance, in 2017, the
American Heart Association (AHA) recorded stroke costs as US$ 34 billion in the
U.S. every year, which includes medicines for the treatment of stroke and cost
of health care services.
Asia pacific is the fastest
growing region in the tissue plasminogen activator market, owing to increasing
demand drug coupled with rising stroke incidences in the region. According to
WHO, Indonesia, Philippines, China, and India have highest rates of stroke,
which is 186.3, 134.7, 128, and 71.5, respectively, as recorded in 2017.
Global Tissue Plasminogen
Activator Market: Competitive Landscape
Key players operating in the
global tissue plasminogen activator market include Bayer AG, Abcam, Calbiochem,
Merck & Company, Roche, Sekisui Diagnostics, Genentech, Sigma-Aldrich, Taj
Pharmaceuticals, and Cadila Healthcare Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2469
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment